FTC Study: In FY 2012, Branded Drug Firms Significantly Increased theUse of Potential Pay-for-Delay Settlements to Keep Generic Competitors off the Market
Date
In Fiscal Year (FY) 2012, the number of potentially anticompetitive patent dispute settlements between branded and generic drug companies increased significantly compared with FY 2011, jumping from 28...